Iterum Therapeutics plc - Ordinary Share (ITRM)

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade tariffs eroded risk appetite.

Iterum Therapeutics' Orlynvah receives FDA approval for treating uncomplicated UTIs in adult women, marking its first approved indication and a U.S. first for oral penems.

ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!

ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.

Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin.